# A Comparative Study of LY900014 to Insulin Lispro (Humalog) in Healthy Participants

> **NCT03286751** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 42 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** LY900014
- **DRUG:** Insulin Lispro

## Key facts

- **NCT ID:** NCT03286751
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-13
- **Primary completion:** 2018-02-06
- **Final completion:** 2018-02-06
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2020-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03286751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03286751, "A Comparative Study of LY900014 to Insulin Lispro (Humalog) in Healthy Participants". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03286751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*